# Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

> **NCT00440973** · PHASE2 · TERMINATED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 6 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT00440973
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2007-10
- **Final completion:** 2007-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** contract issues
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440973, "Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00440973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*